Literature DB >> 12577943

Assessment of depression in patients with chronic hepatitis: effect of interferon treatment.

J Koskinas1, P Merkouraki, E Manesis, S Hadziyannis.   

Abstract

INTRODUCTION/AIM: Chronic viral hepatitis and its treatment with interferon (IFN) have an impact on patients' quality of life. The purpose of this study was to evaluate the degree of depression in patients with chronic viral hepatitis before and during IFN therapy. PATIENTS/
METHODS: Our study group comprised 132 patients, 38 with chronic hepatitis C (26 males, 12 females), 36 with chronic hepatitis B (29 males, 7 females), and 58 individuals with no chronic disease (24 males, 34 females). Depression was assessed using the Zung Self-Rating Depression Scale and the corresponding SDS index.
RESULTS: At baseline, patients with viral hepatitis and healthy controls had similar SDS indexes. During treatment, a significant increase in the SDS index was observed in both HBV and HCV patients (p < 0.001), which returned to the baseline levels after treatment. During IFN therapy, the SDS indexes were higher in HCV compared to HBV patients and women compared to men (p = 0.001 and p = 0.008, respectively), and there was a >5- fold increased frequency to develop severe depression.
CONCLUSIONS: IFN-induced depression occurs more frequently in HCV than HBV patients and in women than men. Monitoring during treatment is mandatory in order to maximize treatment adherence. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12577943     DOI: 10.1159/000067682

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  16 in total

Review 1.  Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders.

Authors:  George M Slavich; Julia Sacher
Journal:  Psychopharmacology (Berl)       Date:  2019-07-29       Impact factor: 4.530

2.  Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.

Authors:  Debika Bhattacharya; T Umbleja; F Carrat; R T Chung; M G Peters; F Torriani; J Andersen; J S Currier
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

3.  Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment.

Authors:  E Sinakos; E Gigi; T Lalla; A-L Bellou; A Sykja; E Orphanou; E Vrettou; V Tsapas; M Raptopoulou
Journal:  Hippokratia       Date:  2010-04       Impact factor: 0.471

Review 4.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

Review 5.  Sex differences in the neuro-immune consequences of stress: Focus on depression and anxiety.

Authors:  Mandakh Bekhbat; Gretchen N Neigh
Journal:  Brain Behav Immun       Date:  2017-02-16       Impact factor: 7.217

6.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

7.  Association of T and non-T cell cytokines with anhedonia: Role of gender differences.

Authors:  Manish K Jha; Andrew H Miller; Abu Minhajuddin; Madhukar H Trivedi
Journal:  Psychoneuroendocrinology       Date:  2018-05-12       Impact factor: 4.905

8.  Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression.

Authors:  Mona Moieni; Michael R Irwin; Ivana Jevtic; Richard Olmstead; Elizabeth C Breen; Naomi I Eisenberger
Journal:  Neuropsychopharmacology       Date:  2015-01-19       Impact factor: 7.853

9.  Depression following pegylated interferon-alpha: characteristics and vulnerability.

Authors:  Francis E Lotrich; Mordechai Rabinovitz; Patricia Gironda; Bruce G Pollock
Journal:  J Psychosom Res       Date:  2007-08       Impact factor: 3.006

10.  Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C.

Authors:  Nader Dbouk; Miguel R Arguedas; Aasim Sheikh
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.